Hengrui's HER3 ADC SHR-A2009 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC
May 18, 2026 18:37
CST Updated
May 19, 10:14
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer